Does pharmacogenomic testing meaningfully improve antidepressant treatment outcomes when looking only at patients taking phase I hepatically metabolized drugs? A little

Joseph F. Goldberg

doi:10.4088/JCP.19com13119

Does pharmacogenomic testing meaningfully improve antidepressant treatment outcomes when looking only at patients taking phase I hepatically metabolized drugs? A little

Joseph F. Goldberg

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Original language	English
Journal	Journal of Clinical Psychiatry
Volume	80
Issue number	6
DOIs	https://doi.org/10.4088/JCP.19com13119
State	Published - 2019

Access to Document

10.4088/JCP.19com13119

Cite this

@article{f5e089878ff042cab02252e95b62d48a,

title = "Does pharmacogenomic testing meaningfully improve antidepressant treatment outcomes when looking only at patients taking phase I hepatically metabolized drugs? A little",

author = "Goldberg, {Joseph F.}",

year = "2019",

doi = "10.4088/JCP.19com13119",

language = "English",

volume = "80",

journal = "Journal of Clinical Psychiatry",

issn = "0160-6689",

publisher = "Physicians Postgraduate Press Inc.",

number = "6",

}

TY - JOUR

T1 - Does pharmacogenomic testing meaningfully improve antidepressant treatment outcomes when looking only at patients taking phase I hepatically metabolized drugs? A little

AU - Goldberg, Joseph F.

PY - 2019

Y1 - 2019

UR - http://www.scopus.com/inward/record.url?scp=85076669719&partnerID=8YFLogxK

U2 - 10.4088/JCP.19com13119

DO - 10.4088/JCP.19com13119

M3 - Review article

C2 - 31846245

AN - SCOPUS:85076669719

SN - 0160-6689

VL - 80

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

IS - 6

ER -